Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Payables (2016 - 2025)

Historic Payables for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $1.7 million.

  • Assembly Biosciences' Payables rose 2606.74% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 2606.74%. This contributed to the annual value of $585000.0 for FY2024, which is 2689.8% up from last year.
  • As of Q3 2025, Assembly Biosciences' Payables stood at $1.7 million, which was up 2606.74% from $743000.0 recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Payables ranged from a high of $3.6 million in Q1 2021 and a low of $461000.0 during Q4 2023
  • Over the past 5 years, Assembly Biosciences' median Payables value was $1.3 million (recorded in 2024), while the average stood at $1.6 million.
  • In the last 5 years, Assembly Biosciences' Payables crashed by 8150.82% in 2023 and then soared by 7612.14% in 2024.
  • Quarter analysis of 5 years shows Assembly Biosciences' Payables stood at $2.7 million in 2021, then decreased by 6.24% to $2.5 million in 2022, then tumbled by 81.51% to $461000.0 in 2023, then grew by 26.9% to $585000.0 in 2024, then surged by 187.69% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $743000.0 for Q2 2025, and $875000.0 during Q1 2025.